secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001654954-25-000453
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate
--------------------------------------------------------------------------------

- Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.
- To date, completed exchanges with two investors for 14,200 shares of common stock.
- Director Laith Yaldoo manages two entities expected to participate in the Exchange Program.
- Exchange eliminates investor rights to future revenue share cash and a $5.3M buy-out option.
- Investors retain Warrants issued under the original Participation Agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495425000453/0001654954-25-000453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495425000453/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-000453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer